ANDA Filing Not Willful Patent Infringement Per Se, Federal Circuit Rules
The mere filing of an Abbreviated New Drug Application (ANDA) cannot constitute an act of willful infringement compensable by attorney's fees under the Hatch-Waxman Act, the U.S. Court of Appeals for...To view the full article, register now.
Already a subscriber? Click here to view full article